Karen Vines, MD
Family Medicine · Hoover, ALNPI 1417392010
Payments from drug & device makers
Across 693 payments — averaging $15.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- AbbVie$2K
- AstraZeneca$1K
- Lilly USA, LLC$887
- Pfizer$872
- Boehringer Ingelheim$586
- plus $4K from 24 others
What the payments were for
- Food & beverage$11,008100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 183 | $2,357 |
| AbbVie(2 entities) | 114 | $1,751 |
| AstraZeneca | 43 | $1,022 |
| Lilly USA, LLC | 56 | $887 |
| Pfizer | 57 | $872 |
| Boehringer Ingelheim | 37 | $586 |
| Amgen(2 entities) | 22 | $444 |
| GSK | 22 | $373 |
| Takeda Pharmaceuticals U.S.A., Inc. | 19 | $356 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 18 | $328 |
| Exact Sciences | 18 | $292 |
| Amarin Pharma, Inc. | 23 | $264 |
| Merck | 16 | $253 |
| Abbott | 11 | $207 |
| Biohaven Pharmaceutical Holding Company Ltd. | 12 | $187 |
| Dexcom, Inc. | 5 | $179 |
| Biohaven Pharmaceuticals, Inc. | 6 | $132 |
| Kowa Pharmaceuticals America, Inc. | 6 | $77 |
| Shield Therapeutics Inc | 4 | $76 |
| Currax Pharmaceuticals LLC | 5 | $74 |
| Axsome Therapeutics, Inc. | 2 | $53 |
| Paratek Pharmaceuticals, Inc. | 3 | $47 |
| Boston Scientific | 2 | $37 |
| Sumitomo Pharma America, Inc. | 2 | $35 |
| Genentech USA, Inc. | 2 | $30 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| Sanofi-aventis U.S. LLC | 1 | $23 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Aytu Biopharma, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,008 in reported general payments places this provider in the 90th percentile of 1,680 family medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 157 | $167,505 |
| OzempicSemaglutide | 58 | $92,184 |
| EliquisApixaban | 34 | $31,965 |
| FarxigaDapagliflozin Propanediol | 28 | $31,505 |
| JanuviaSitagliptin Phosphate | 22 | $23,295 |
| InvokanaCanagliflozin | 25 | $19,142 |
| Tresiba Flextouch U-100Insulin Degludec | 19 | $15,318 |
| JardianceEmpagliflozin | 14 | $14,512 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $13,084 |
| Rosuvastatin Calcium | 294 | $6,163 |
| SynthroidLevothyroxine Sodium | 33 | $4,141 |
| VyvanseLisdexamfetamine Dimesylate | 11 | $3,991 |
| Atorvastatin Calcium | 278 | $3,113 |
| Pitavastatin Calcium | 14 | $2,998 |
| Amlodipine Besylate | 381 | $2,826 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $887 | $167,505157 claims |
| Novo NordiskOzempic | $2,357 | $92,18458 claims |
| PfizerEliquis | $872 | $31,96534 claims |
| AstraZenecaFarxiga | $1,022 | $31,50528 claims |
| MerckJanuvia | $253 | $23,29522 claims |
| Boehringer IngelheimJardiance | $586 | $14,51214 claims |
| GSKTrelegy Ellipta | $373 | $13,08417 claims |
| AbbVieSynthroid | $1,751 | $4,14133 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $356 | $3,99111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,680 family medicine providers in Alabama.
Other family medicine in Hoover
- Michael VaughnBirmingham$9.9M
- William NixonGuntersville$7.1M
- Randall QuinnCullman$5.4M
- Matthew CaldwellAthens$4.1M
- Michael CarterHuntsville$3.4M
- Howard RubensteinSaraland$3.3M
- Randle MiddletonHuntsville$3.3M
- Aaron KarrSheffield$3.1M
- Nidal MorrarFoley$3M
- Timothy HowardHuntsville$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.